PLXNA4 and neoplasm: PLXNA4 mutations, more frequent in R patients, have been shown to promote Cytotoxic T-lymphocyte infiltration in pre-clinical tumor models, as PLXNA4 behaves as a negative checkpoint regulating T-cell migration and proliferation26.